Close

BeiGene (BGNE) Announces Positive Topline Results for Global Phase 3 Trial of Tislelizumab in Esophageal Squamous Cell Carcinoma

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 4/24/2024

1. TSLA
2. ENPH
3. TXN
4. SPOT
5. V
6. KMB
7. BA
8. FI
9. MSCI
10. STX


Go back to BeiGene (BGNE) Announces Positive Topline Results for Global Phase 3 Trial of Tislelizumab in Esophageal Squamous Cell Carcinoma
(NASDAQ: BGNE) Delayed: 143.70 +4.71 (3.39%)
Previous Close $138.99    52 Week High $36.76 
Open $143.45    52 Week Low $22.51 
Day High $146.22    P/E N/A 
Day Low $142.65    EPS $0.00 
Volume 64,705